<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334630</url>
  </required_header>
  <id_info>
    <org_study_id>TP00599</org_study_id>
    <nct_id>NCT03334630</nct_id>
  </id_info>
  <brief_title>DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>DIAMOND-AF</acronym>
  <official_title>A Randomized Controlled Clinical Evaluation of the DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the DIAMOND-AF study is to establish the safety and effectiveness of the&#xD;
      DiamondTemp System for the treatment of drug refractory, recurrent, symptomatic paroxysmal&#xD;
      atrial fibrillation in patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DIAMOND-AF study is a prospective, single blind, 1:1 randomized controlled study being&#xD;
      performed at multiple centers in the United States, Canada and Europe. The study will&#xD;
      evaluate the safety and effectiveness of the DiamondTemp System used for ablation in patients&#xD;
      with paroxysmal atrial fibrillation (AF). Subjects will be randomized for treatment with&#xD;
      either the DiamondTemp Ablation Catheter or the TactiCath™ Quartz Contact Force Ablation&#xD;
      Catheter manufactured by Abbott. Patients will be followed for 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Actual">December 3, 2019</completion_date>
  <primary_completion_date type="Actual">November 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Freedom From a Composite of Pre-specified Serious Adverse Events (SAEs)</measure>
    <time_frame>Within 30-days or 6-months after index ablation procedure</time_frame>
    <description>The primary safety endpoint is defined as freedom from a composite of serious adverse events (SAE) occurring within 30-days and clinically symptomatic pulmonary vein stenosis through 6-months post-index ablation procedure, as adjudicated by an independent Clinical Events Committee (CEC) for relatedness to the procedure or device.&#xD;
The primary safety device- or procedure-related SAE composite will be the combined rate of the following events:&#xD;
Atrioesophageal fistula&#xD;
Bleeding complication&#xD;
Cardiac tamponade / perforation&#xD;
Death&#xD;
Extended hospitalization&#xD;
Myocardial infarction&#xD;
Pericarditis&#xD;
Phrenic nerve paralysis&#xD;
Pulmonary edema&#xD;
Pulmonary vein stenosis&#xD;
Stroke post-ablation&#xD;
Thromboembolism&#xD;
Transient ischemic attack (TIA) post-ablation&#xD;
Vagal nerve injury&#xD;
Vascular access complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness: Freedom From Documented Atrial Fibrillation(AF), Atrial Flutter(AFL) and Atrial Tachycardia(AT) Episodes Following the Blanking Period (3M Post-ablation) Through the End of the Effectiveness Evaluation Period (12M Post-ablation).</measure>
    <time_frame>3-12M (3-12 months) after index ablation procedure</time_frame>
    <description>The primary effectiveness failure is defined by any of the following events:&#xD;
Inability to electrically isolate all accessible targeted pulmonary veins during the ablation procedure&#xD;
Documented episodes of AF, AFL or AT lasting ≥ 30 seconds in duration as evidenced by electrocardiographic data during the effectiveness evaluation period&#xD;
DC cardioversion for AF, AFL or AT during the effectiveness evaluation period&#xD;
A repeat ablation procedure to treat AF, AFL or AT during the effectiveness evaluation period&#xD;
Use of a new or modification to existing Class I-IV anti-arrhythmic drug (AAD) regimen to treat AF, AFL or AT recurrence during the effectiveness evaluation period&#xD;
Use of a non-study device for ablation of any AF targets during the index or repeat ablation procedure during the blanking period&#xD;
More than one (1) repeat ablation procedure during the blanking period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Duration of Individual Radiofrequency (RF) Ablations (Seconds)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Mean duration of individual RF ablations (seconds) during the index ablation procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cumulative RF Time Per Procedure (Minutes)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Mean cumulative RF time per procedure (minutes) during the index ablation procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From a Composite of SAE Occurring Within 7-days</measure>
    <time_frame>Within 7-days after the index ablation procedure</time_frame>
    <description>Freedom from a composite of SAE occurring within 7-days post-index ablation procedure as adjudicated by an independent CEC for relatedness to the procedure or device.&#xD;
The device- or procedure-related SAE composite will be the combined rate of the following events:&#xD;
Atrioesophageal fistula&#xD;
Bleeding complication&#xD;
Cardiac tamponade / perforation&#xD;
Death&#xD;
Extended hospitalization&#xD;
Myocardial infarction&#xD;
Pericarditis&#xD;
Phrenic nerve paralysis&#xD;
Pulmonary edema&#xD;
Pulmonary vein stenosis&#xD;
Stroke post-ablation&#xD;
Thromboembolism&#xD;
Transient ischemic attack (TIA) post-ablation&#xD;
Vagal nerve injury&#xD;
Vascular access complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Documented AF, AT and AFL Episodes in the Absence of Class I and III Anti-arrhythmic Drugs (AADs).</measure>
    <time_frame>3-12 months after index ablation procedure</time_frame>
    <description>Freedom from documented AF, AT and AFL episodes following the blanking period through 12-month follow-up post-ablation procedure in the absence of class I and III anti-arrhythmic drug therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Acute Procedural Success</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Rate of acute procedural success is defined as confirmation of electrical isolation of PVs via assessment of entrance block at least 20 minutes following the last ablation around the respective PV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Single Procedure Success With Freedom From Documented AF, AT and AFL at 12 Months.</measure>
    <time_frame>Index ablation procedure through 12-months after index ablation procedure</time_frame>
    <description>Rate of single procedure success is defined as the rate of subjects treated with one single ablation procedure during study participation and with freedom from documented AF, AT and AFL at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Single Procedure Success With Freedom From ALL Primary Effectiveness Endpoint Failure Criteria.</measure>
    <time_frame>Index ablation procedure through 12-months after index ablation procedure</time_frame>
    <description>Rate of single procedure success is defined as the rate of subjects treated with one single ablation procedure during study participation and with freedom from ALL primary effectiveness endpoint failure criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Occurrence of Electrically Reconnected Pulmonary Veins (PVs)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Rate of occurrence of electrically reconnected PVs following a 20-minute waiting period assessed by entrance block at index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulated Changes in Quality of Life (QOL) Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire</measure>
    <time_frame>Baseline, 6-months after index ablation and 12-months after index ablation</time_frame>
    <description>Accumulated changes in QOL using the AF QOL Survey (AFEQT Questionnaire) from baseline through 6 and 12 months following ablation procedure.&#xD;
The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire is an atrial fibrillation-specific health-related quality of life Questionnaire. The overall AFEQT score can range from 0 to 100, with 0 corresponding to complete disability and 100 corresponding to no disability. So a higher AFEQT score means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Changes Measured Using the National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>Baseline, pre-discharge after index ablation and 12-months after index ablation procedure</time_frame>
    <description>Neurological changes measured using the NIH stroke scale between baseline and post-ablation (pre-discharge visit) and at 12 months post-ablation procedure.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The total NIHSS score can range from 0 to 42, with 0 indicating no stroke symptoms and 42 indicating extremely severe stroke symptoms. So a higher NIHSS score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Time (Minutes)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Total procedure time (minutes) at index procedure is defined as time of first assigned ablation catheter insertion into the vasculature to time of last procedural ablation catheter removed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve Initial Pulmonary Vein Isolation (PVI) (Minutes)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Time to achieve initial PVI (minutes) at index procedure is defined as time of delivery of first RF ablation with the assigned ablation catheter until confirmation of PVI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Treatment Device Time (Minutes)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Total treatment device time (minutes) at index procedure is defined as time of delivery of first RF ablation with the assigned ablation treatment catheter to removal of the treatment catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of RF Ablations Per Procedure</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Total number of RF ablations per procedure at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Fluid Infused Through the Ablation Catheter (mL)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Total fluid infused through the assigned ablation catheter (mL) at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Fluoroscopy Time (Minutes)</measure>
    <time_frame>Index ablation procedure</time_frame>
    <description>Total fluoroscopy time (minutes) at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Re-hospitalizations Due to Atrial Fibrillation Recurrence After Blanking Period</measure>
    <time_frame>3-12 months after index ablation procedure</time_frame>
    <description>Number of re-hospitalizations due to atrial fibrillation recurrence after blanking period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">482</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>DiamondTemp Ablation Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TactiCath Quartz Ablation Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DiamondTemp Ablation catheter</intervention_name>
    <description>a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
    <arm_group_label>DiamondTemp Ablation Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TactiCath Quartz Ablation catheter</intervention_name>
    <description>a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
    <arm_group_label>TactiCath Quartz Ablation Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        STUDY INCLUSION CRITERIA- Candidates must meet ALL the following criteria to be enrolled in&#xD;
        the DIAMOND-AF study:&#xD;
&#xD;
          1. Above eighteen (18) years of age or of legal age to give informed consent specific to&#xD;
             state and national law.&#xD;
&#xD;
          2. Subjects with a history of symptomatic, paroxysmal atrial fibrillation (PAF) who have&#xD;
             had ≥2 episodes of PAF reported within the 6 months prior to index ablation procedure&#xD;
             with a physician note indicating recurrent, self-terminating AF.&#xD;
&#xD;
          3. At least one episode of PAF documented by electrocardiographic data within the 12&#xD;
             months prior to index ablation procedure.&#xD;
&#xD;
          4. Refractory to at least one Class I-IV AAD for treatment of PAF.&#xD;
&#xD;
          5. Suitable candidate for intra-cardiac mapping and ablation of arrhythmia.&#xD;
&#xD;
          6. Subject agrees to comply with study procedures and be available (geographically&#xD;
             stable) for follow-up visits for at least 12 months after enrollment.&#xD;
&#xD;
          7. Subject is willing and able to provide written consent.&#xD;
&#xD;
        STUDY EXCLUSION CRITERIA - Candidates will be excluded from the DIAMOND-AF study if any of&#xD;
        the following conditions apply within the following timeframes:&#xD;
&#xD;
        At time of enrollment and/or prior to procedure:&#xD;
&#xD;
          1. AF secondary to electrolyte imbalance, thyroid disease or reversible or non-cardiac&#xD;
             cause.&#xD;
&#xD;
          2. LA diameter &gt; 5.5 cm.&#xD;
&#xD;
          3. LVEF &lt; 35%.&#xD;
&#xD;
          4. Currently NYHA Class III or IV or exhibits uncontrolled heart failure.&#xD;
&#xD;
          5. BMI &gt; 40 kg/m2.&#xD;
&#xD;
          6. LA ablation, septal closure device or mitral valve surgical procedure at any time&#xD;
             prior to enrollment.&#xD;
&#xD;
          7. Presence of intramural thrombus, tumor or abnormality that precludes vascular access,&#xD;
             catheter introduction or manipulation.&#xD;
&#xD;
          8. Coagulopathy, bleeding diathesis or suspected procoagulant state&#xD;
&#xD;
          9. Sepsis, active systemic infection or fever (&gt;100.5°F / 38°C) within a week prior to&#xD;
             the ablation procedure.&#xD;
&#xD;
         10. Significant restrictive or obstructive pulmonary disease or chronic respiratory&#xD;
             condition.&#xD;
&#xD;
         11. Renal failure requiring dialysis or renal compromise that in the investigator's&#xD;
             judgement would increase risk to the subject or deem the subject inappropriate to&#xD;
             participate in the study.&#xD;
&#xD;
         12. Known allergies or intolerance to anticoagulant and antiplatelet therapies to be used&#xD;
             in conjunction with the study or contrast sensitivity that cannot be adequately&#xD;
             pre-treated prior to the ablation procedure.&#xD;
&#xD;
         13. Positive pregnancy test results for female subjects of childbearing potential or&#xD;
             breast feeding.&#xD;
&#xD;
         14. Enrollment in a concurrent clinical study that in the judgement of the investigator&#xD;
             would impact study outcomes.&#xD;
&#xD;
         15. Acute or chronic medical condition that in the judgment of the investigator would&#xD;
             increase risk to the subject or deem the subject inappropriate to participate in the&#xD;
             study.&#xD;
&#xD;
         16. Life expectancy &lt; 12 months based on medical history or the medical judgement of the&#xD;
             investigator.&#xD;
&#xD;
             Within 1 month of enrollment or just prior to procedure:&#xD;
&#xD;
         17. Documented LA thrombus upon imaging.&#xD;
&#xD;
         18. Creatinine &gt;2.5mg/dl or creatinine clearance &lt;30mL/min.&#xD;
&#xD;
             Within 2 months of enrollment:&#xD;
&#xD;
         19. Regularly (uninterrupted) prescribed amiodarone.&#xD;
&#xD;
             Within 3 months of enrollment:&#xD;
&#xD;
         20. Significant GI bleed.&#xD;
&#xD;
         21. MI, unstable angina, cardiac surgery or coronary intervention.&#xD;
&#xD;
             Within 6 months of enrollment:&#xD;
&#xD;
         22. CABG procedure.&#xD;
&#xD;
         23. ICD, CRT leads or pacemaker implant procedure.&#xD;
&#xD;
         24. Documented stroke, CVA, TIA or suspected neurological event.&#xD;
&#xD;
             Within 12 months of enrollment:&#xD;
&#xD;
         25. An episode of AF lasting &gt;7 days in duration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Kautzner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut klinické a experimentální medicíny (IKEM)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Maddox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom McElderry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grandview Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck School Of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sequoia Hospital</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trident Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Medical Centre</name>
      <address>
        <city>Toronto</city>
        <state>Newmarket/Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce</name>
      <address>
        <city>Praha</city>
        <state>Prague</state>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Anne's University Hospital</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Klinicke a Experimentalni Mediciny (IKEM)</name>
      <address>
        <city>Praha</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 3</state>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Tonkin</name>
      <address>
        <city>Villeurbanne</city>
        <state>Lyon</state>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <state>Milano</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo di Mestre</name>
      <address>
        <city>Mestre</city>
        <state>Venezia</state>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Iwasawa J, Koruth JS, Petru J, Dujka L, Kralovec S, Mzourkova K, Dukkipati SR, Neuzil P, Reddy VY. Temperature-Controlled Radiofrequency Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017 Aug 1;70(5):542-553. doi: 10.1016/j.jacc.2017.06.008.</citation>
    <PMID>28750697</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <results_first_submitted>November 13, 2020</results_first_submitted>
  <results_first_submitted_qc>November 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 9, 2020</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ablation</keyword>
  <keyword>electrophysiology</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter</keyword>
  <keyword>paroxysmal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03334630/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Revision I</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03334630/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Revision G</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03334630/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Revision F</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03334630/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Revision E</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03334630/Prot_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Revision D</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03334630/Prot_005.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Revision C</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03334630/Prot_006.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Revision H</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03334630/Prot_007.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment/randomization occurred between 06NOV2017 and 26OCT2018 across 23 sites in the US, Canada and Europe.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>DiamondTemp Ablation Catheter</title>
          <description>Catheter ablation to treat paroxysmal atrial fibrillation using the DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
        </group>
        <group group_id="P2">
          <title>TactiCath Quartz Ablation Catheter</title>
          <description>Catheter ablation to treat atrial fibrillation using the TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="239"/>
                <participants group_id="P2" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrollment closed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject not treated with study ablation due to technical difficulties</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject unable to complete 12-month follow-up visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DiamondTemp Ablation Catheter</title>
          <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
        </group>
        <group group_id="B2">
          <title>TactiCath Quartz Ablation Catheter</title>
          <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="239"/>
            <count group_id="B2" value="243"/>
            <count group_id="B3" value="482"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="11.1"/>
                    <measurement group_id="B2" value="63.0" spread="10.4"/>
                    <measurement group_id="B3" value="62.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="336"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: Freedom From a Composite of Pre-specified Serious Adverse Events (SAEs)</title>
        <description>The primary safety endpoint is defined as freedom from a composite of serious adverse events (SAE) occurring within 30-days and clinically symptomatic pulmonary vein stenosis through 6-months post-index ablation procedure, as adjudicated by an independent Clinical Events Committee (CEC) for relatedness to the procedure or device.&#xD;
The primary safety device- or procedure-related SAE composite will be the combined rate of the following events:&#xD;
Atrioesophageal fistula&#xD;
Bleeding complication&#xD;
Cardiac tamponade / perforation&#xD;
Death&#xD;
Extended hospitalization&#xD;
Myocardial infarction&#xD;
Pericarditis&#xD;
Phrenic nerve paralysis&#xD;
Pulmonary edema&#xD;
Pulmonary vein stenosis&#xD;
Stroke post-ablation&#xD;
Thromboembolism&#xD;
Transient ischemic attack (TIA) post-ablation&#xD;
Vagal nerve injury&#xD;
Vascular access complications</description>
        <time_frame>Within 30-days or 6-months after index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Freedom From a Composite of Pre-specified Serious Adverse Events (SAEs)</title>
          <description>The primary safety endpoint is defined as freedom from a composite of serious adverse events (SAE) occurring within 30-days and clinically symptomatic pulmonary vein stenosis through 6-months post-index ablation procedure, as adjudicated by an independent Clinical Events Committee (CEC) for relatedness to the procedure or device.&#xD;
The primary safety device- or procedure-related SAE composite will be the combined rate of the following events:&#xD;
Atrioesophageal fistula&#xD;
Bleeding complication&#xD;
Cardiac tamponade / perforation&#xD;
Death&#xD;
Extended hospitalization&#xD;
Myocardial infarction&#xD;
Pericarditis&#xD;
Phrenic nerve paralysis&#xD;
Pulmonary edema&#xD;
Pulmonary vein stenosis&#xD;
Stroke post-ablation&#xD;
Thromboembolism&#xD;
Transient ischemic attack (TIA) post-ablation&#xD;
Vagal nerve injury&#xD;
Vascular access complications</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Free from primary safety event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="227"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not free from primary safety event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the DiamondTemp arm is inferior to the Control arm. Alternative hypothesis: the DiamondTemp arm is non-inferior to the Control arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assuming a Control composite SAE freedom rate of 93.5%, 226 subjects per group yields 80% power to detect a non-inferiority margin of -6.5% between treatment groups at a significance level of 0.025.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance is 0.025.</p_value_desc>
            <method>Farrington-Manning non-inferiority test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0324</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0132</ci_lower_limit>
            <ci_upper_limit>0.0779</ci_upper_limit>
            <estimate_desc>Estimated risk difference = DiamondTemp composite SAE freedom rate - Control composite SAE freedom rate = 3.24% = 0.0324</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness: Freedom From Documented Atrial Fibrillation(AF), Atrial Flutter(AFL) and Atrial Tachycardia(AT) Episodes Following the Blanking Period (3M Post-ablation) Through the End of the Effectiveness Evaluation Period (12M Post-ablation).</title>
        <description>The primary effectiveness failure is defined by any of the following events:&#xD;
Inability to electrically isolate all accessible targeted pulmonary veins during the ablation procedure&#xD;
Documented episodes of AF, AFL or AT lasting ≥ 30 seconds in duration as evidenced by electrocardiographic data during the effectiveness evaluation period&#xD;
DC cardioversion for AF, AFL or AT during the effectiveness evaluation period&#xD;
A repeat ablation procedure to treat AF, AFL or AT during the effectiveness evaluation period&#xD;
Use of a new or modification to existing Class I-IV anti-arrhythmic drug (AAD) regimen to treat AF, AFL or AT recurrence during the effectiveness evaluation period&#xD;
Use of a non-study device for ablation of any AF targets during the index or repeat ablation procedure during the blanking period&#xD;
More than one (1) repeat ablation procedure during the blanking period</description>
        <time_frame>3-12M (3-12 months) after index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness: Freedom From Documented Atrial Fibrillation(AF), Atrial Flutter(AFL) and Atrial Tachycardia(AT) Episodes Following the Blanking Period (3M Post-ablation) Through the End of the Effectiveness Evaluation Period (12M Post-ablation).</title>
          <description>The primary effectiveness failure is defined by any of the following events:&#xD;
Inability to electrically isolate all accessible targeted pulmonary veins during the ablation procedure&#xD;
Documented episodes of AF, AFL or AT lasting ≥ 30 seconds in duration as evidenced by electrocardiographic data during the effectiveness evaluation period&#xD;
DC cardioversion for AF, AFL or AT during the effectiveness evaluation period&#xD;
A repeat ablation procedure to treat AF, AFL or AT during the effectiveness evaluation period&#xD;
Use of a new or modification to existing Class I-IV anti-arrhythmic drug (AAD) regimen to treat AF, AFL or AT recurrence during the effectiveness evaluation period&#xD;
Use of a non-study device for ablation of any AF targets during the index or repeat ablation procedure during the blanking period&#xD;
More than one (1) repeat ablation procedure during the blanking period</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Free from primary effectiveness failure criteria</title>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not free from primary effectiveness failure criteria</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the DiamondTemp arm is inferior to the Control arm. Alternative hypothesis: the DiamondTemp arm is non-inferior to the Control arm.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Assuming a Control primary effectiveness rate of 65%, 229 subjects per group yields 80% power to detect a non-inferiority margin of -12.5% between treatment groups at a significance level of 0.025.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance is 0.025.</p_value_desc>
            <method>Farrington-Manning non-inferiority test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.034</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
            <estimate_desc>Estimated risk difference = DiamondTemp composite SAE freedom rate - Control composite SAE freedom rate = 3.4% = 0.034</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Duration of Individual Radiofrequency (RF) Ablations (Seconds)</title>
        <description>Mean duration of individual RF ablations (seconds) during the index ablation procedure</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Duration of Individual Radiofrequency (RF) Ablations (Seconds)</title>
          <description>Mean duration of individual RF ablations (seconds) during the index ablation procedure</description>
          <population>Subjects with measure available.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="5.3"/>
                    <measurement group_id="O2" value="32.6" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the population means for the DiamondTemp and Control groups are not different.&#xD;
Alternative hypothesis: the population means for the DiamondTemp and Control groups are different.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Four secondary endpoints will be tested for superiority over Control hierarchically with pre-specified order:&#xD;
Mean duration of individual RF ablations (seconds)&#xD;
Mean cumulative RF time per procedure (minutes)&#xD;
Total fluoroscopy time (minutes)&#xD;
Total procedure time (minutes) The first secondary endpoint needs to be significant at the two-sided 0.05 alpha level before the next one can be tested at the same threshold. Testing stops once an endpoint is determined to be non-significant.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance is 0.05 two-sided. The p-value is adjusted for multiple comparisons via the hierarchical testing approach.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.2</ci_lower_limit>
            <ci_upper_limit>-14.6</ci_upper_limit>
            <estimate_desc>Difference is DiamondTemp minus Control. A lower value is better.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cumulative RF Time Per Procedure (Minutes)</title>
        <description>Mean cumulative RF time per procedure (minutes) during the index ablation procedure</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cumulative RF Time Per Procedure (Minutes)</title>
          <description>Mean cumulative RF time per procedure (minutes) during the index ablation procedure</description>
          <population>Subjects with measure available.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="8.1"/>
                    <measurement group_id="O2" value="29.8" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the population means for the DiamondTemp and Control groups are not different.&#xD;
Alternative hypothesis: the population means for the DiamondTemp and Control groups are different.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Four secondary endpoints will be tested for superiority over Control hierarchically with pre-specified order:&#xD;
Mean duration of individual RF ablations (seconds)&#xD;
Mean cumulative RF time per procedure (minutes)&#xD;
Total fluoroscopy time (minutes)&#xD;
Total procedure time (minutes) The first secondary endpoint needs to be significant at the two-sided 0.05 alpha level before the next one can be tested at the same threshold. Testing stops once an endpoint is determined to be non-significant.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance is 0.05 two-sided. The p-value is adjusted for multiple comparisons via the hierarchical testing approach.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>-9.8</ci_upper_limit>
            <estimate_desc>Difference is DiamondTemp minus Control. A lower value is better.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From a Composite of SAE Occurring Within 7-days</title>
        <description>Freedom from a composite of SAE occurring within 7-days post-index ablation procedure as adjudicated by an independent CEC for relatedness to the procedure or device.&#xD;
The device- or procedure-related SAE composite will be the combined rate of the following events:&#xD;
Atrioesophageal fistula&#xD;
Bleeding complication&#xD;
Cardiac tamponade / perforation&#xD;
Death&#xD;
Extended hospitalization&#xD;
Myocardial infarction&#xD;
Pericarditis&#xD;
Phrenic nerve paralysis&#xD;
Pulmonary edema&#xD;
Pulmonary vein stenosis&#xD;
Stroke post-ablation&#xD;
Thromboembolism&#xD;
Transient ischemic attack (TIA) post-ablation&#xD;
Vagal nerve injury&#xD;
Vascular access complications</description>
        <time_frame>Within 7-days after the index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From a Composite of SAE Occurring Within 7-days</title>
          <description>Freedom from a composite of SAE occurring within 7-days post-index ablation procedure as adjudicated by an independent CEC for relatedness to the procedure or device.&#xD;
The device- or procedure-related SAE composite will be the combined rate of the following events:&#xD;
Atrioesophageal fistula&#xD;
Bleeding complication&#xD;
Cardiac tamponade / perforation&#xD;
Death&#xD;
Extended hospitalization&#xD;
Myocardial infarction&#xD;
Pericarditis&#xD;
Phrenic nerve paralysis&#xD;
Pulmonary edema&#xD;
Pulmonary vein stenosis&#xD;
Stroke post-ablation&#xD;
Thromboembolism&#xD;
Transient ischemic attack (TIA) post-ablation&#xD;
Vagal nerve injury&#xD;
Vascular access complications</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Free from composite SAEs within 7 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="230"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not free from composite SAEs within 7 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Documented AF, AT and AFL Episodes in the Absence of Class I and III Anti-arrhythmic Drugs (AADs).</title>
        <description>Freedom from documented AF, AT and AFL episodes following the blanking period through 12-month follow-up post-ablation procedure in the absence of class I and III anti-arrhythmic drug therapy.</description>
        <time_frame>3-12 months after index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Documented AF, AT and AFL Episodes in the Absence of Class I and III Anti-arrhythmic Drugs (AADs).</title>
          <description>Freedom from documented AF, AT and AFL episodes following the blanking period through 12-month follow-up post-ablation procedure in the absence of class I and III anti-arrhythmic drug therapy.</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Free from documented AF, AT and AFL episodes in the absence of class I and III AADs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not free from documented AF, AT and AFL episodes in the absence of class I and III AADs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Acute Procedural Success</title>
        <description>Rate of acute procedural success is defined as confirmation of electrical isolation of PVs via assessment of entrance block at least 20 minutes following the last ablation around the respective PV.</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Acute Procedural Success</title>
          <description>Rate of acute procedural success is defined as confirmation of electrical isolation of PVs via assessment of entrance block at least 20 minutes following the last ablation around the respective PV.</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Acute procedural success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not acute procedural success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Single Procedure Success With Freedom From Documented AF, AT and AFL at 12 Months.</title>
        <description>Rate of single procedure success is defined as the rate of subjects treated with one single ablation procedure during study participation and with freedom from documented AF, AT and AFL at 12 months.</description>
        <time_frame>Index ablation procedure through 12-months after index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Single Procedure Success With Freedom From Documented AF, AT and AFL at 12 Months.</title>
          <description>Rate of single procedure success is defined as the rate of subjects treated with one single ablation procedure during study participation and with freedom from documented AF, AT and AFL at 12 months.</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Single procedure success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not single procedure success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Single Procedure Success With Freedom From ALL Primary Effectiveness Endpoint Failure Criteria.</title>
        <description>Rate of single procedure success is defined as the rate of subjects treated with one single ablation procedure during study participation and with freedom from ALL primary effectiveness endpoint failure criteria.</description>
        <time_frame>Index ablation procedure through 12-months after index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Single Procedure Success With Freedom From ALL Primary Effectiveness Endpoint Failure Criteria.</title>
          <description>Rate of single procedure success is defined as the rate of subjects treated with one single ablation procedure during study participation and with freedom from ALL primary effectiveness endpoint failure criteria.</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Single procedure success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not single procedure success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Occurrence of Electrically Reconnected Pulmonary Veins (PVs)</title>
        <description>Rate of occurrence of electrically reconnected PVs following a 20-minute waiting period assessed by entrance block at index procedure.</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Occurrence of Electrically Reconnected Pulmonary Veins (PVs)</title>
          <description>Rate of occurrence of electrically reconnected PVs following a 20-minute waiting period assessed by entrance block at index procedure.</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Occurrence of electrically reconnected PVs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No occurrence of electrically reconnected PVs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulated Changes in Quality of Life (QOL) Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire</title>
        <description>Accumulated changes in QOL using the AF QOL Survey (AFEQT Questionnaire) from baseline through 6 and 12 months following ablation procedure.&#xD;
The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire is an atrial fibrillation-specific health-related quality of life Questionnaire. The overall AFEQT score can range from 0 to 100, with 0 corresponding to complete disability and 100 corresponding to no disability. So a higher AFEQT score means a better outcome.</description>
        <time_frame>Baseline, 6-months after index ablation and 12-months after index ablation</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulated Changes in Quality of Life (QOL) Using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire</title>
          <description>Accumulated changes in QOL using the AF QOL Survey (AFEQT Questionnaire) from baseline through 6 and 12 months following ablation procedure.&#xD;
The Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire is an atrial fibrillation-specific health-related quality of life Questionnaire. The overall AFEQT score can range from 0 to 100, with 0 corresponding to complete disability and 100 corresponding to no disability. So a higher AFEQT score means a better outcome.</description>
          <population>Subjects with measure available.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="23.1"/>
                    <measurement group_id="O2" value="25.5" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="23.4"/>
                    <measurement group_id="O2" value="30.1" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurological Changes Measured Using the National Institutes of Health Stroke Scale (NIHSS)</title>
        <description>Neurological changes measured using the NIH stroke scale between baseline and post-ablation (pre-discharge visit) and at 12 months post-ablation procedure.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The total NIHSS score can range from 0 to 42, with 0 indicating no stroke symptoms and 42 indicating extremely severe stroke symptoms. So a higher NIHSS score means a worse outcome.</description>
        <time_frame>Baseline, pre-discharge after index ablation and 12-months after index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Neurological Changes Measured Using the National Institutes of Health Stroke Scale (NIHSS)</title>
          <description>Neurological changes measured using the NIH stroke scale between baseline and post-ablation (pre-discharge visit) and at 12 months post-ablation procedure.&#xD;
The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The total NIHSS score can range from 0 to 42, with 0 indicating no stroke symptoms and 42 indicating extremely severe stroke symptoms. So a higher NIHSS score means a worse outcome.</description>
          <population>Subjects with measure available.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.30"/>
                    <measurement group_id="O2" value="0" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.36"/>
                    <measurement group_id="O2" value="-0.1" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedure Time (Minutes)</title>
        <description>Total procedure time (minutes) at index procedure is defined as time of first assigned ablation catheter insertion into the vasculature to time of last procedural ablation catheter removed.</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time (Minutes)</title>
          <description>Total procedure time (minutes) at index procedure is defined as time of first assigned ablation catheter insertion into the vasculature to time of last procedural ablation catheter removed.</description>
          <population>Subjects with measure available.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7" spread="46.2"/>
                    <measurement group_id="O2" value="115.4" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the population means for the DiamondTemp and Control groups are not different.&#xD;
Alternative hypothesis: the population means for the DiamondTemp and Control groups are different.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Four secondary endpoints will be tested for superiority over Control hierarchically with pre-specified order:&#xD;
Mean duration of individual RF ablations (seconds)&#xD;
Mean cumulative RF time per procedure (minutes)&#xD;
Total fluoroscopy time (minutes)&#xD;
Total procedure time (minutes) The first secondary endpoint needs to be significant at the two-sided 0.05 alpha level before the next one can be tested at the same threshold. Testing stops once an endpoint is determined to be non-significant.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.4</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
            <estimate_desc>Difference is DiamondTemp minus Control. A lower value is better.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve Initial Pulmonary Vein Isolation (PVI) (Minutes)</title>
        <description>Time to achieve initial PVI (minutes) at index procedure is defined as time of delivery of first RF ablation with the assigned ablation catheter until confirmation of PVI.</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve Initial Pulmonary Vein Isolation (PVI) (Minutes)</title>
          <description>Time to achieve initial PVI (minutes) at index procedure is defined as time of delivery of first RF ablation with the assigned ablation catheter until confirmation of PVI.</description>
          <population>Subjects with measure available.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" spread="29.9"/>
                    <measurement group_id="O2" value="69.4" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Treatment Device Time (Minutes)</title>
        <description>Total treatment device time (minutes) at index procedure is defined as time of delivery of first RF ablation with the assigned ablation treatment catheter to removal of the treatment catheter.</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Total Treatment Device Time (Minutes)</title>
          <description>Total treatment device time (minutes) at index procedure is defined as time of delivery of first RF ablation with the assigned ablation treatment catheter to removal of the treatment catheter.</description>
          <population>Subjects with measure available.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" spread="34.0"/>
                    <measurement group_id="O2" value="91.4" spread="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of RF Ablations Per Procedure</title>
        <description>Total number of RF ablations per procedure at index procedure</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of RF Ablations Per Procedure</title>
          <description>Total number of RF ablations per procedure at index procedure</description>
          <population>Subjects with measure available.</population>
          <units>counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" spread="32.9"/>
                    <measurement group_id="O2" value="71.1" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fluid Infused Through the Ablation Catheter (mL)</title>
        <description>Total fluid infused through the assigned ablation catheter (mL) at index procedure</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fluid Infused Through the Ablation Catheter (mL)</title>
          <description>Total fluid infused through the assigned ablation catheter (mL) at index procedure</description>
          <population>Subjects with measure available.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332.2" spread="120.8"/>
                    <measurement group_id="O2" value="785.2" spread="351.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fluoroscopy Time (Minutes)</title>
        <description>Total fluoroscopy time (minutes) at index procedure</description>
        <time_frame>Index ablation procedure</time_frame>
        <population>Subjects with measure available.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fluoroscopy Time (Minutes)</title>
          <description>Total fluoroscopy time (minutes) at index procedure</description>
          <population>Subjects with measure available.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="10.2"/>
                    <measurement group_id="O2" value="12.8" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the population means for the DiamondTemp and Control groups are not different.&#xD;
Alternative hypothesis: the population means for the DiamondTemp and Control groups are different.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Four secondary endpoints will be tested for superiority over Control hierarchically with pre-specified order:&#xD;
Mean duration of individual RF ablations (seconds)&#xD;
Mean cumulative RF time per procedure (minutes)&#xD;
Total fluoroscopy time (minutes)&#xD;
Total procedure time (minutes) The first secondary endpoint needs to be significant at the two-sided 0.05 alpha level before the next one can be tested at the same threshold. Testing stops once an endpoint is determined to be non-significant.</non_inferiority_desc>
            <p_value>0.8528</p_value>
            <p_value_desc>The a priori threshold for statistical significance is 0.05 two-sided. The p-value is adjusted for multiple comparisons via the hierarchical testing approach.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Difference is DiamondTemp minus Control. A lower value is better.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Re-hospitalizations Due to Atrial Fibrillation Recurrence After Blanking Period</title>
        <description>Number of re-hospitalizations due to atrial fibrillation recurrence after blanking period</description>
        <time_frame>3-12 months after index ablation procedure</time_frame>
        <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>DiamondTemp Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
          <group group_id="O2">
            <title>TactiCath Quartz Ablation Catheter</title>
            <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Re-hospitalizations Due to Atrial Fibrillation Recurrence After Blanking Period</title>
          <description>Number of re-hospitalizations due to atrial fibrillation recurrence after blanking period</description>
          <population>Intention-to-treat population: all randomized subjects are included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 re-hospitalization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 re-hospitalization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 re-hospitalizations</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events (AEs) observed by the Investigator or staff during a physical or laboratory examination, interventional procedure or mentioned by the subject, either spontaneously or upon questioning, were recorded on an AE case report form, from the time of signed informed consent through the twelve-month follow-up visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DiamondTemp Ablation Catheter</title>
          <description>Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter&#xD;
DiamondTemp Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
        </group>
        <group group_id="E2">
          <title>TactiCath Quartz Ablation Catheter</title>
          <description>Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter&#xD;
TactiCath Quartz Ablation catheter: a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Blood loss anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cranial nerve injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Postoperative hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Venous injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>IVth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Phrenic nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Seizure like phenomena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device pacing issue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Colostomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="239"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="239"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="239"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="239"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>While the language in each agreement may vary slightly, in general it states that the Principal Investigator (PI) agrees to not independently discuss/publish trial results until a multi-center publication is released. If the multi-center publication is not submitted within one year after study completion across all centers, PIs may publish the results pertaining to their activities. PI must submit this request to the Sponsor for review/comment at least forty-five (45) days prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katie Flor, Principal Clinical Research Specialist</name_or_title>
      <organization>Medtronic</organization>
      <phone>+1 763 526 9651</phone>
      <email>katie.j.flor@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

